OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
July 03, 2021
Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.
Bi-layer tablets are an under-utilized option that can be employed to help reduce treatment burden, but their formulation is more complex than for conventional monolayer products.
June 11, 2021
CPI has revealed an agreement with DFE Pharma, making it the latest partner of the Medicines Manufacturing Innovation Centre (MMIC) collaboration.
May 03, 2021
Applying a QbD approach helps address excipient variability and other quality features.
April 22, 2021
DFE’s new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers high-quality excipient technology and services.
April 03, 2021
Topical drugs are attractive to patients, but these complex products pose challenges for formulators.
March 03, 2021
Without an independent approval pathway for novel excipients, true pharmaceutical innovation could be stymied.
Various strategies to improve bioavailability are being continuously evaluated, affording greater commercial prospects for the future.
February 25, 2021
The company will join the network of approved manufacturers of the lipid excipients.
February 10, 2021
The importance of characterizing excipients, supply chain security, and the role of novel excipients are explored.